Preparing the trial collection…
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Opioid-use research landscape

Psilocybin Clinical Trials for Opioid Use Disorder

Explore clinical trial records that explicitly connect psilocybin research with opioid use disorder or opioid-related registered conditions.

Explore this trial map All recruiting trials

Registry status is not a guarantee of local availability, eligibility, safety, or efficacy. Confirm every participation decision in the authoritative ClinicalTrials.gov record.

11matching trials
8currently recruiting
14registry-listed sites

Registry facts checkedAug 10, 2026 01:26 UTC

Live registry synthesis

Status, geography, and study phase

The collection matches explicit opioid terminology in registry condition fields. It does not merge unrelated substance-use diagnoses or imply evidence of efficacy.

Recruitment status

  1. Recruiting8
  2. Withdrawn2
  3. Terminated1

Leading countries

  1. United States9
  2. Canada1

Trial phases

  1. Phase 28
  2. Phase 12
Interactive map

Explore matching study locations

The map opens with this collection’s filter applied. Its controls can further narrow status, phase, condition, country, intervention, and dates.

Open full map
Server-rendered source index

11 matching registry records

Every factual summary is crawlable without JavaScript. Use the direct registry link for current eligibility, contacts, and site availability.

RecruitingNCT06001749

Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer

Yvan Beaussant, MD, MSci

Conditions
Opioid-Related Disorders · Pain Management · Pain Management and Care · Advanced Cancer
Phase
Phase 2
Enrollment
15 estimated
Locations
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Registry updated
2026-08-05
Open registry recordTracker record
RecruitingNCT06067737

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

Johns Hopkins University

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
90 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-07-17
Open registry recordTracker record
TerminatedNCT06624137

Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects

Yale University

Conditions
OCD · Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) · Healthy Volunteer
Phase
Phase not reported
Enrollment
5 actual
Locations
Connecticut Mental Health Center, Hamden, Connecticut, United States · West Haven VA Medical Center, West Haven, Connecticut, United States
Registry updated
2026-07-09
Open registry recordTracker record
RecruitingNCT06810310

Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder

University of Pennsylvania

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
24 estimated
Locations
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Registry updated
2026-07-09
Open registry recordTracker record
RecruitingNCT04161066

Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation

University of Wisconsin, Madison

Conditions
Opioid Use Disorder
Phase
Phase 1
Enrollment
10 estimated
Locations
University of Wisconsin, Madison, Wisconsin, United States
Registry updated
2026-07-07
Open registry recordTracker record
RecruitingNCT06160284

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Yale University

Conditions
Opioid Use Disorder
Phase
Phase 1
Enrollment
12 estimated
Locations
Yale University, New Haven, Connecticut, United States
Registry updated
2026-07-07
Open registry recordTracker record
WithdrawnNCT06005662

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

Johns Hopkins University

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
0 actual
Locations
Johns Hopkins University, Baltimore, Maryland, United States
Registry updated
2026-02-23
Open registry recordTracker record
RecruitingNCT06796062

A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment

NYU Langone Health

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
480 estimated
Locations
Duke City Recovery Toolbox, Albuquerque, New Mexico, United States · University of New Mexico, Albuquerque, New Mexico, United States · StartCare, Brooklyn, New York, United States · +2 more
Registry updated
2026-01-23
Open registry recordTracker record
RecruitingNCT05585229

Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study

University of British Columbia

Conditions
Opioid Dependence · Chronic Pain
Phase
Phase 2
Enrollment
10 estimated
Locations
University of British Columbia - Okanagan Campus, Kelowna, British Columbia, Canada
Registry updated
2025-12-04
Open registry recordTracker record
RecruitingNCT06786325

A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?

Anna Rose Childress, Ph.D.

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
36 estimated
Locations
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Registry updated
2025-10-29
Open registry recordTracker record
WithdrawnNCT05242029

A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use

Johns Hopkins University

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
0 actual
Locations
No mapped site reported
Registry updated
2024-02-02
Open registry recordTracker record
Related research views

Move between curated condition, country, phase, and recruiting views without losing direct source provenance.

Recruitment

Conditions

Countries

Phases

Method and accountability

How this collection is maintained

Automatic refresh: counts, facets, records, and the map update from the tracker after scheduled ClinicalTrials.gov refreshes. The registry remains authoritative.

Rights-safe scope: the page exposes allowlisted factual metadata. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.

Editorial review: collection definitions, limitations, corrections, and authorship are documented in the editorial and methodology policy.